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ABSTRACT 
OBESITY-INDUCED INFLAMMATION IN HUMAN MAMMARY TISSUE: A 
POTENTIAL MICROENVIRONMENT FAVORABLE TO THE DEVELOPMENT 
OF POSTMENOPAUSAL BREAST CANCER VIA THE WNT SIGNALING 
PATHWAY 
SEPTEMBER 2015 
AGATHE ROUBERT, B.S., EASTERN KENTUCKY UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Zhenhua Liu 
 
In the United States, over one third of adult women are obese, and one in eight 
women will be diagnosed with breast cancer in their lifetime. Obesity has been shown 
to be a risk factor for postmenopausal breast cancer and is associated with increased 
aggressiveness and poor prognosis regardless of menopausal status. However, the 
mechanisms involved in the relationship between obesity and breast cancer are still 
not fully understood. Wnt signaling is often elevated in breast tumors (~60%) and is 
suspected to play a key role in cancer development. It has been shown that 
inflammatory cytokines, such as TNF-α, IL-1β, IFNγ, are potential mediators in the 
regulation of Wnt-signaling. We hypothesize that the low-grade inflammatory state 
associated with obesity is present in human mammary tissue, stimulates Wnt activity, 
and thereby leads to the development of breast cancer. In this project, we propose to 
1) characterize the inflammatory cytokine profile, including IFN-γ, IL-1β, IL-2, IL-6, 
IL-8, and TNF-α, in the mammary tissue of normal weight, overweight, and obese 
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postmenopausal women using a high performance electrochemiluminescence 
immunoassay;  2) determine the influences of the obesity-induced pro-inflammatory 
cytokines on Wnt-signaling by examining gene expression of seven Wnt-signaling 
target genes using real-time PCR; and 3) define the causality  between TNF-α, one of 
the mot critical inflammatory cytokines, and Wnt signaling by measuring the gene 
expression of the Wnt targets in samples from normal to overweight and obese 
postmenopausal women treated with anti-TNF-α antibody or TNF-α recombinant 
protein respectively. We expect to define a novel mechanism that obesity mediates the 
development of postmenopausal breast via inflammation-driven Wnt signaling. 
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CHAPTER 1 
INTRODUCTION 
There is mounting evidence that suggests that Wnt may play a critical role in 
the link between obesity-induced inflammation and the development of breast cancer, 
but the exact mechanisms involved are still unknown. The relationship between 
proinflammatory cytokines in the breasts of obese women, Wnt activity, and breast 
cancer risk has not yet been investigated. We aim to characterize the inflammatory 
cytokine profile and level of Wnt signaling activity in the breasts of obese women, 
and determine whether TNF-α neutralization results in reduced Wnt activation. Upon 
completion of the study, we should have gained new knowledge on the relationship 
between obesity and Wnt activity in the breasts, and the results may uncover a new 
area worth targeting by therapeutics for the treatment of breast cancer. 
It is now well established that obesity is a risk factor for the development of 
postmenopausal breast cancer (Carmichael, 2006), and excess adiposity is associated 
with increased tumor size and poor prognosis regardless of menopausal status (Berdaz 
et al., 2004). The Million Women Study revealed that an increase of 10 units in BMI 
is associated with a relative risk of development of postmenopausal breast cancer of 
1.40 (Reeves et al., 2007). The EPIC study revealed that weight gain during adulthood 
is also a risk factor for the development of post-menopausal breast cancer (Lahmann 
et al., 2005). Among non-users of hormone replacement therapy (HRT), the relative 
risk of breast cancer increased by 22 and 53% in women gaining 2-15kg and >15kg, 
respectively, compared with women with stable weight. With 36.1% of American 
women being obese and 65.8% being overweight or obese (Ogden et al., 2014), the 
relationship between obesity and breast cancer is a source of concern, and could 
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explain why 1 in 8 American women (12.3%) will be diagnosed with breast cancer in 
their lifetime (National Cancer Institute, 2015).  
Because the majority of breast tumors express hormone receptors (estrogen 
and/or progesterone) (Howlader et al., 2013), sex hormones and especially estrogen, 
whose production is elevated in obese postmenopausal women, are often regarded as 
key factors in breast tumor development. However, the chronic inflammatory state 
associated with obesity has grown into a prime suspect to explain the link between 
obesity and breast cancer development (Rose & Vona-Davis, 2013). Indeed, elevated 
levels of macrophages and crown-like structures (CLS), characteristic of obesity, are 
found in the fat tissue of obese individuals and result in an increased production of 
pro-inflammatory cytokines by inflamed adipocytes (McArdle et al., 2013). CLS have 
been observed in the breast tissue of obese women with breast cancers (Morris et al., 
2011), and those cytokines are suspected to activate several pro-inflammatory and 
pro-tumorigenic pathways (Gilbert & Slingerland, 2013). 
The Wnt signaling pathway, which results in the translocation of β-catenin in 
the nucleus and the activation of target genes involved in cell proliferation, polarity, 
apoptosis and differentiation, is commonly upregulated in breast cancer (Howe & 
Brown, 2004). Activated β-catenin correlates with increased cyclinD1 expression, a 
Wnt target and oncogene, and is associated with poor prognosis (Lin et al., 2000). 
Some evidence show that Wnt signaling may be activated by pro-inflammatory 
cytokines. Our laboratory previously showed that the elevated levels of TNF-α 
present in the colon of obese mice modulate Wnt activity (Liu et al., 2012). Other 
studies have shown that IL-6 and TNF-α both influence the Wnt pathway (Cawthorn 
et al., 2007; Gustafon & Smith, 2006; Isakson et al., 2009). Wnt signaling may thus 
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be an intermediate in the interaction between obesity-induced inflammation and the 
production of cytokines, and the development of breast cancer.   
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CHAPTER 2 
LITERATURE REVIEW 
A. Obesity-induced inflammation and pro-inflammatory cytokines 
It is now well accepted that long term over-nutrition acts as a chronic stressor, 
and obesity is a state of chronic low-grade inflammation, characterized by the 
presence of several pro-inflammatory factors. Levels of C-reactive protein (CRP), an 
acute-phase protein and unspecific marker for inflammation, are elevated in obese 
patients and correlate with the amount of adipose tissue present in the body (Ramos-
Nino, 2013). This inflammatory environment is suspected to promote the 
development of many obesity-associated chronic diseases, including several types of 
cancers. Tumor initiation, promotion and progression are encouraged by 
overexpression of inflammatory mediators.  Ramos-Nino (2013) also reports that anti-
inflammatory drugs have been shown to improve cancer incidence and progression, 
thus further supporting the hypothesis of a link between inflammation and cancer 
development. 
Although adipose tissues are an important source of several pro-inflammatory 
cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, 
the interferon (IFN) family, etc. (Clément & Vignes, 2009), not all adipocytes have 
the same phenotype. Obesity is characterized by the presence of excess white adipose 
tissue (WAT), especially in the visceral area (central obesity) which is more 
predictive of obesity-associated comorbidity and mortality than subcutaneous 
adiposity (Ramos-Nino, 2013), and is characterized by a more inflammatory 
phenotype (Balistreri, Caruso, & Candore, 2010) and increased number of 
macrophages in adipose tissue (van Kruijsdijk,  van der Wall, & Visseren, 2009). The 
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ATTICA study in Greece revealed that central obesity was associated with elevated 
serum levels of CRP, TNF-α and IL-6 (53%, 30%, and 42% higher than participants 
with normal fat distribution respectively), and that waist and waist-to-hip ratio, 
indicators of visceral adiposity, were better measurements than BMI, especially in 
women (Panagiotakos et al., 2005). Park, Park and Yu (2005) found similar results 
and therefore declare the accumulation of visceral fat a key factor in the up-regulation 
of obesity-associated inflammation.  
The exact mechanisms linking obesity, stress and inflammation have not been 
fully understood yet, but over-nutrition triggers a chronic adaptive response that 
further promotes the development of an inflammatory state. A vicious cycle is 
established between the stressor and the prolongation of the adaptive response, which 
both contribute to the development and maintenance of the chronic inflammatory 
conditions characteristic of obesity. In healthy adipose tissue adipocyte expansion 
occurs with minimal inflammation via the effective recruitment of adipose progenitors 
and proper extra cellular matrix remodeling (Sun, Kusminski & Scherer, 2011). 
However, in metabolically-impaired obese individuals, excessive expansion of 
adipocytes results in hypertrophy, hypoxia, massive inflammation and fibrosis, and 
the release of many proinflammatory and mitogenic factors that can have dramatic 
consequences on the development of chronic diseases, including cancers (Hefetz-Sela 
& Scherer, 2013). Lipolysis increases and free fatty acids (FFAs) are released, which 
can activate inflammatory pathways, but WAT also have endocrine functions which 
stimulate the inflammatory response (McArdle et al., 2013).  
Expansion of WAT results in the increased secretion of inflammatory 
adipokines by adipocytes, including IL-6, IL-1β, TNF-α and leptin, and decreased 
secretion of anti-inflammatory adiponectin (McArdle et al., 2013). The altered 
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expression of those adipokines has been associated with several metabolic disorders. 
Adipocytes also secrete monocyte chemoattractant protein (MCP)-1 which promotes 
monocytes infiltration and adhesion molecules which also attract monocytes. 
Monocytes can then differentiate into macrophages, which then secrete cytokines, 
thus participating in the establishment of inflammatory conditions. Macrophage 
infiltration and polarization seems to be a driving factor in the promotion of 
inflammation. While in normal conditions adipose tissues have anti-inflammatory 
functions via the action of M2 macrophages and the secretion of anti-inflammatory 
cytokines, in obese patients we generally observe a change in the cytokine profile 
with the release of iNOS (nitric oxide synthase) and pro-inflammatory cytokines by 
more activated M1 macrophages (Kraakman et al., 2014). WAT expansion and 
inflammation, and the resulting production of cytokines by adipocytes and resident 
macrophages, lead to the recruitment of monocytes which differentiate into more M1 
macrophages and result in the further production of inflammatory cytokines.  
Although adipocytes are the main components, WAT contain many other cells 
which all participate in the maintenance and promotion of the chronic inflammatory 
state (McArdle et al., 2013). Pre-adipocytes normally differentiate into adipocytes 
during adipogenesis, but in obese individuals we observe that inflammatory cytokines 
IL-6, IL-1β, TNF-α and IFN-γ impair preadipocytes maturation and their number 
increases. Pre-adipocytes also secrete inflammatory mediators including IL-6 and 
MCP-1 at even greater levels than mature adipocytes, and fibroblast growth factor 
which acts with TNF-α and IFN-γ to recruit monocytes and neutrophils, which can 
then differentiate into macrophages. Preadipocytes produce proinflammatory 
cytokines to promote their development, and these cytokines attract monocytes which 
are converted to macrophages with the help of high leptin levels and thus also 
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contribute to the production of proinflammatory cytokines, which further impairs 
preadipocyte to adipocyte maturation (Gilbert & Slingerland, 2013). Furthermore, 
adiponectin, an anti-inflammatory protein with antiangiogenic and antiproliferative 
properties that promotes the maturation of preadipocytes and is secreted by mature 
adipocytes, is downregulated in obese individuals. While mature adipocytes secrete 
both inflammatory leptin and anti-inflammatory adiponectin, preadipocytes secrete 
primarily leptin and in obese individuals leptin expression is upregulated while 
adiponectin levels negatively correlate with body fat. Other cytokines associated with 
obesity also interfere with preadipocytes maturation. Simons et al. (2005) showed that 
exposure to IL-1β, TNF-α, IFN-γ, and TGF-β inhibited adipogenesis and completely 
blocked adiponectin secretion (although interestingly IL-6, a pro-inflammatory 
cytokine and hallmark of obesity-induced inflammation, had no effect). IL-1β and 
TNF-α also significantly increased leptin production. They further showed that IL-1β, 
TNF-α, and IFN-γ induced preadipocyte proliferation and inhibited adipocyte 
formation by preventing growth arrest and promoting re-entrance in the S phase. 
Additionally, pre-adipocyte factor-1 (Pref-1), a protein that prevents adipogenesis, 
increases with the number of macrophages in metabolically altered WAT (McArdle et 
al., 2013). Preadipocytes thus also contribute to the inflammatory conditions and 
some believe that the disruption of adipogenesis, the inability of adipocytes to 
properly expand to store the excess energy consumed, might significantly contribute 
to the metabolic conditions associated with obesity (Christodoulides et al., 2008).  
In the stroma-vascular fraction, many cell types are present including 
macrophages and cells involved in the immune response, which are increased in 
obesity and have a phenotype that further promotes the inflammatory condition. 
Macrophages are believed to play a critical role in adipocyte inflammation, but other 
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immune cells also seem to be influenced by obesity. Regulatory T-cells (Treg), which 
secrete anti-inflammatory cytokines, inhibit macrophage migration and promote the 
M2 macrophage phenotypes, are down-regulated during weight gain, while pro-
inflammatory T helper 1 (TH1) cells are upregulated (McArdle et al., 2013). IFN-γ is 
secreted by TH1 and stimulates the switch from M2 to M1 macrophages, and thus 
leads to the further production of pro-inflammatory cytokines IL-1, IL-6 and TNF-α. 
The secretion of inflammatory cytokines by expanding adipocytes is suspected to play 
an important role in the development and maintenance of the obesity-induced 
inflammation (Karalis et al., 2009). In chronic over-nutrition, the WAT mass 
continues to increase, and the inflammatory conditions are maintained (Figure 1). 
 
 
TNF-α is one of the most studied proinflammatory cytokines. Hotamisligil, 
Shargill, and Spiegelman were the first to demonstrate in 1993 that most TNF-α 
Figure 1: Metabolic changes and inflammation in white adipose tissue of obese 
individuals. 
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mRNA was expressed by the adipocytes (in opposition to nonadipose cells, or the 
stromal-vascular fraction) and that obese adipose tissue secrete about twice as much 
TNF- α as lean tissue (Hotamisligil, Shargill, & Spiegelman, 1993). It was first 
believed that TNF-α, a macrophage-derived factor that could induce necrosis in tumor 
cells and is involved in the adaptive response of the immune system, could be used as 
an anticancer agent, but it has now been shown to promote carcinogenesis and cancer 
progression (van Kruijsdijk,  van der Wall, & Visseren, 2009). It plays a key role in 
the normal response to infection, but dysregulation of its production can be harmful 
(Bradley, 2008). Isakson et al. (2009) showed that exposure of preadipocytes to TNF-
α completely prevented their normal differentiation into adipose cells, and promoted a 
partial transdifferentiation of the preadipocytes to assume a macrophage-like 
phenotype, evidenced by elevated gene expression of chemokines and cytokines, 
including IL-1β, TNF-α, IL-6 and IL-8, thus participating in the maintenance of the 
inflammatory condition. It also seems to prevent the transcription of anti-
inflammatory adiponectin (Tilg & Moschen, 2006).  The presence of TNF-α has been 
shown to activate several inflammatory pathways, including the NF-κB pathway, 
which results in the expression of many inflammation-related genes and has been 
associated with tumor growth, metastasis, and survival (Prieto-Hontoria et al., 2011), 
and the Wnt signaling pathway, involved in several cancers (Oguma et al., 2008; Liu 
et al., 2012). 
IL-1β also participates in the anti-adipogenic action of macrophages (Gagnon 
et al., 2013), and, along with other members of the IL-1 family, also activates the NF-
κB pathway (Korkaya et al., 2011). It also stimulates other cytokines, including IL-6 
and IL-8, and promotes angiogenesis, tumor growth, and metastasis. It participates in 
the angiogenic switch, during which the activity of anti-angiogenic factors decreases 
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while pro-angiogenic factors are activated (Voronov, Carmi & Apte, 2014). In 
tumors, it can recruit myeloid cells from the bone marrow and stimulate secretion of 
pro-inflammatory and pro-angiogenic molecules, it prevents myeloid cells maturation 
thus maintaining them in a pro-invasive and immunosuppressive state, it promotes the 
production of VEGF (vascular endothelial growth factor) and pro-angiogenic factors 
by endothelial cells, and it increases the invasiveness of malignant cells. In the 
absence of IL-1β, inflammation and invasiveness are diminished and myeloid 
inflammatory cells mature into anti-tumor M2 macrophages.  
IL-6 is a hallmark of obesity-induced inflammation and many inflammation-
associated diseases, including cancer, however recently studies have found that IL-6 
may actually have a homeostatic, anti-inflammatory role during obesity-associated 
inflammation (Mauer, Denson & Brüning, 2015). IL-6 may increase insulin-
stimulated glucose disposal in healthy humans rather than promoting type-2 diabetes, 
increase energy expenditure, and be involved in the maintenance of M2 macrophages 
in adipose tissue. However, in cancerogenesis, the presence of IL-6 stimulates tumor 
growth, progression, and relapse. M1 inflammatory macrophages have been shown to 
express high amounts of several inflammatory cytokines including IL-6, which has 
been shown to play an essential role for cancer development in several tissues 
including the breast.  IL-6 is elevated by both obesity and cancer development, and 
studies in mice have shown that obesity may enhance tumor formation by increasing 
IL-6 production and STAT3 activation, and that IL-6 deficiency protects against 
obesity-induced tumor burden. IL-6 promotes tumorigenesis, angiogenesis and 
metastasis, and is associated with poor patient outcome (Korkaya, Liu & Wicha, 
2011). It creates a procarcinogenic, tumorigenic microenvironment by STAT3 
activation, which also activates NF-κB and leads to the production of additional IL-6 
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and IL-8. There is thus a positive feedback loop that further stimulates tumor 
development and metastasis. Similarly to TNF-α, it has also been shown to suppress 
adiponectin transcription and translation (Tilg & Moschen, 2006). Walter et al. (2009) 
proved that adipose stromal cells (ASCs) greatly stimulated the migration and 
invasion of breast cancer cells via the stimulatory actions of IL-6.  
Several pro-inflammatory cytokines are thus stimulated by obesity, via 
inflammation, and seem to be playing a key role in the development of obesity-
associated conditions. IL-8 is also secreted by many cells present in the WAT, 
including mesenchymal, macrophages, and immune cells, and is associated with poor 
cancer prognosis (Korkaya, Liu & Wicha, 2011). As mentioned earlier IFN-γ is also 
involved in the immune response to obesity and the establishment of inflammatory 
conditions. Because inflammatory cytokines are elevated not only in the adipose 
tissue but also in the serum of obese individuals, they are suspected to be able to 
circulate throughout the body and affect the inflammatory status of other tissues, 
including the breasts where they have been found to be elevated in cancer cases 
(Gilbert & Slingerland, 2013). Although the relationship between BMI, cytokines and 
breast cancer has not been fully investigated yet, inflammatory cytokines seem to 
have the potential of being key players in the development of breast tumors. 
 
B. Inflammation and breast cancer 
There is now abundant epidemiological evidence that adiposity is a risk factor 
for the development of breast cancer, especially in post-menopausal women, but the 
mechanisms involved are not fully understood. Estrogen is considered a key factor in 
the development of breast cancer. Indeed, the large majority (about 80%) of breast 
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cancer cases that develop after menopause are tumors that express the estrogen 
receptor (Rose & Vona-Davis, 2014). After menopause, the production of estrogen by 
the ovaries stops, and fat tissue become the main producer of estrogen. Thus, obese 
women are exposed to higher levels of estrogen, which are suspected to increase their 
risk of developing hormone-responsive tumors. Insulin resistance and 
hyperinsulinemia are also suspected to play an important role by causing decreased 
levels of sex-hormone binding globulin (SHBG) and therefore increasing the amount 
of circulating free estrogen (Khan et al., 2013). However, other elements, not 
necessarily mutually exclusive, are most certainly also at play in the development of 
breast cancer, and inflammation is becoming a prime suspect.  
Breast cancer has not been associated with inflammation until recently, and 
inflammation might still not be one of the driving forces in the development of 
mammary tumors in lean women, but evidence now suggests that it plays a critical 
role in the development and progression of breast cancer in obese women (Santander 
et al., 2015). As discussed previously, obesity, and more specifically visceral obesity, 
is associated with inflammation of the adipocytes, while subcutaneous fat is less 
metabolically active. Because of its location breast adipose tissue (bAT) is considered 
subcutaneous fat, but Santander et al. (2015) argue that inflammatory changes are 
likely to occur in bAT as well. Indeed, bAT take up a larger volume than other 
subcutaneous adipose tissues, which may allow them to become hypertrophic and 
hyperplastic, two characteristics of inflamed visceral adipocytes. The presence of 
several cell types in the breast, including adipocytes, preadipocytes, fibroblasts, 
macrophages, etc., may also facilitate cross-talk between them and the production of 
pro-inflammatory molecules. Santander et al. (2015) showed that the cross-talk 
between adipocytes, mammary tumor and macrophages in obese mice results in the 
13 
 
expression of numerous cytokines, chemokines, and growth factors with chemotactic, 
pro-inflammatory, pro-angiogenic and tumor-promoting activities, in the recruitment 
of macrophages via chemokine CCL2 (MCP-1), and in the down-regulation of 
lipolysis, all of which promote inflammation. They thus showed that breast adipocytes 
are metabolically similar to visceral adipocytes. 
The cytokines mentioned previously are highly expressed in adipose tissue of 
obese individuals, but their serum levels are also elevated, which raises the concern 
that they may circulate throughout the body and have inflammatory effects in other 
tissues as well (Gilbert & Slingerland, 2013). They may also be locally produced by 
macrophages within specific tissue. For example, Liu et al. (2012) showed that diet 
induced obesity (DIO) resulted in elevated expression of TNF-α, IL-1β and IL-18 (by 
72%, 44% and 41% respectively) in the colon of obese mice. Cytokines are expressed 
in primary human breast cancers, and although no studies have been performed yet to 
investigate the link between body weight and cytokine expression in breast cancers, it 
is suspected that they contribute to the pro-inflammatory conditions needed for breast 
tumor development and activate cancer-related signaling pathways (Gilbert & 
Slingerland, 2013).  
Subbaramaiah et al. (2011) showed that obesity leads to inflammation of 
mammary tissue in mice, as evidenced by infiltration and activation of macrophages 
in the tissues, and that the resulting elevated levels of inflammatory mediators (i.e. 
TNF-α, IL-1β, and Cox-2) were accompanied by increased levels of aromatase 
mRNA and activity. They attribute the link between proinflammatory gene expression 
and increased aromatase expression to the activation of the NF-κB pathway in the 
mammary gland. Pro-inflammatory cytokines have also been linked to increased 
CYP19 transcription, the gene responsible for cytochrome P450 aromatase, the 
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enzyme that catalyzes the synthesis of estrogen from androgens. The effects of 
inflammation on breast tumor development thus needs to be explored in addition to 
estrogen and aromatase. Indeed, Subbaramaiah et al. (2011) also found that 
macrophages aggregate in crown-like structures (CLS) around the adipocytes in both 
visceral fat and the mammary gland, a phenotype characteristic of obesity-induced 
inflammation that promotes adipocytes necrosis. Formation of CLS was also observed 
in the breast tissue of obese women with breast cancer (Morris et al., 2011).  
Evidence now shows that the interaction between the tumor and the adipocytes 
surrounding it, referred to as cancer-associated adipocytes (CAA), is bidirectional and 
helps promote the establishment of a pro-tumorigenic vicious cycle (Hefetz-Sela & 
Scherer, 2013). The tumor alters the phenotypes of the CAA, and the adipocytes also 
modify the tumors’ characteristics. Santander et al. (2015) showed that bAT 
inflammation in the tumor microenvironment correlates with body weight – obese 
mice have the highest number of macrophages and CLS, overweight mice have fewer, 
and lean mice have the least – and that the same correlation is observed in the bAT 
distal from the tumor. However, bAT in the tumor microenvironment have higher 
inflammation than distal ones, indicating that not only inflammation promotes tumor 
development, but contact with the tumor also promotes inflammation of the 
adipocytes. Dirat et al. (2011) also showed that invasive cancer cells modify the 
phenotype of their surrounding tissues, especially adipocytes. The inflammatory 
cytokines discussed previously may participate in the exchange between adipocytes 
and tumors. Walter et al. (2009) suspect that IL-6 stimulates breast tumor cell 
migration and invasion. Adipose stromal cells (ASC) from bAT (and also from 
visceral adipose tissues) stimulated breast tumor cells migration both in vitro and in 
vivo. While ASC most likely secrete several cytokines and growth factors that could 
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enhance the migratory capacity of breast cancer cells, IL-6 was shown to have great 
influence since its depletion significantly reduced ASC-induced migration and 
invasion. Furthermore, breast tumor cells cocultivated with mature adipocytes 
exhibited an enhanced invasive phenotype, and adipocytes isolated from tumor 
samples exhibit overexpression of several inflammatory markers, including IL-6 (but 
not IL-1β or TNF-α) (Dirat et al., 2011). Higher levels of IL-6 were associated with 
larger tumor size and lymph nodes involvement. CAAs seem to promote tumor 
growth and survival. IL-8 expression has also been shown to be elevated in metastatic 
tumors compared to non-metastatic tumors and is thus suspected to participate in 
cancer migration and invasion (De Larco et al., 2001). IL-8 is induced by other 
inflammatory cytokines (IL-1β and TNF-α), and the effect of these two cytokines on 
IL-8 expression is about 180 times greater in metastatic cancer cell lines. Moreover, 
metastatic cancer cell lines had basal levels of IL-8 expression equal to or higher than 
non-metastatic cancer cell lines even after treatment with IL-1β or TNF-α, thus further 
confirming the link between IL-8 and metastatic potential.  
There is most likely more than just one pathway responsible for the link 
between obesity and breast cancer, but pro-inflammatory cytokines produced by 
adipocytes are suspected to play a central role. By influencing aromatase expression 
they may contribute to the initiation of breast cancer, especially ER-positive breast 
tumors, but their inflammation-promoting activity is likely to also have a strong 
influence on cancer progression and may explain why obesity is associated with poor 
prognosis. 
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C. Wnt signaling and Cancer 
Several inflammatory pathways have been investigated to explain the 
relationship between adiposity, inflammation and inflammatory cytokines, and cancer 
development, and the Wnt/β-catenin signaling pathway has recently drawn interest. 
The Wnt pathway is involved in the regulation of a number of mechanisms during 
embryonic development and the homeostasis of many adult tissues (Tree, 2013). It is 
involved in cell proliferation, cell polarity, and cell identity and therefore its 
dysregulation has been linked to several disorders, including some types of cancers. 
There are one canonical and two non-canonical Wnt pathways, but the latter are less 
well understood and the canonical Wnt pathway, or Wnt/β-catenin pathway, is the 
most studied for its link with cancer. The link between Wnt signaling and breast 
cancer was established in 1982 when Roel Nusse and Harold Varmus, from the 
University of California, San Francisco, showed that mammary gland tumorigenesis 
was induced by a virus that caused a loss-of-function mutation of a gene they named 
Int1 (Klaus & Birchmeier, 2008).  
The canonical Wnt pathway is described as a two-state model, either on or off, 
which controls the level of accumulation of β-catenin in the nucleus (Tree, 2013). 
When the pathway is not activated, casein kinase 1 (CK1) and glycogen synthase 
kinase 3 (GSK3), part of the cytoplasmic destruction complex along APC 
(adenomatous polyposis coli) and Axin, sequentially phosphorylate β-catenin which 
can then be recognized by β-Trcp, an E3 ubiquitine ligase, and degraded. Cytoplasmic 
levels of β-catenin thus remain low, which prevents β-catenin translocation to the 
nucleus. In the on state the Wnt/β-catenin pathway is activated by Wnt proteins, 
present in the extracellular space, that bind to two receptors: a Frizzled (Fz) receptor, 
a seven pass transmembrane protein, and a low-density lipoprotein related receptor 
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(LRP5 or 6), a single pass transmembrane protein. There are 19 Wnt proteins and 10 
Fz receptors in mammals, but not all proteins can bind to all receptors. The formation 
of the tripartite complex leads to the recruitment of the cytoplasmic protein 
Dishevelled (Dsh) which causes the phosphorylation of LRP and the recruitment of 
parts of the destruction complex, resulting in its deactivation. β-catenin thus cannot be 
degraded and accumulates in the cytoplasm and eventually translocates to the nucleus. 
There it displaces the inhibitor Groucho and forms a complex with the DNA binding 
proteins TCF/LEF, which results in the transcription of Wnt target genes, some of 
whom regulate cell faith (Figure 2). The Wnt pathway remains turned off in the 
absence of Wnt proteins or in the presence of inhibitors, including SFRP, DKK and 
WIF.  
 
 
Wnt signaling is involved in the regulation of tissue development and 
homeostasis in many organs, and therefore its dysregulation can lead to tumor growth 
Figure 2: Scheme of Wnt signaling.  
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and development. Abnormal Wnt activity has been observed in several types of 
cancers. It can be activated via a mutation in APC, β-catenin or other elements of the 
Wnt pathway, as it is the case in over 90% of colorectal tumors (Luu et al., 2004), but 
in breast cancers mutations are rare. However, accumulation of β-catenin in the 
cytoplasm and/or nucleus is observed in up to 60% of breast tumors, while it is not 
detected in normal breast tissue (Howe & Brown, 2004). Moreover, cytoplasmic and 
nuclear β-catenin accumulation and the accompanying increase in the expression of 
target genes are associated with poor prognosis.  
Overexpression of some Wnt proteins has been reported in several studies, and 
the expression of Wnt inhibitors, including WIF1, DKK1 and sFRPs, may also be 
impaired. Suzuki et al. (2008) reported methylation of Wnt antagonists in a number of 
breast cancer cell lines as well as in primary breast tumors. They found that sFRP1, 
sFRP2, sFRP5 and DKK1 were commonly absent or downregulated in many breast 
cancer cell lines while they were all expressed in normal tissue. They also observed 
methylation of sFRP1, sFRP2 and sFRP5 in the large majority of cell lines tested (in 
7, 11 and 10 cell lines respectively out of 11 tested), while methylation of DKK1 was 
detected in only 3 cell lines. These antagonists were also methylated in primary breast 
tumors, although a little less commonly. Finally, they showed that sFRPs suppress 
breast cancer cells growth, suggesting that sFRPs, and potentially DKK1, may have 
tumor suppressor functions in breast cancer. Matsuda et al. (2008) also provided 
evidence that SFRP1 may regulate Wnt activity in breast cancer cells and play a role 
in cancer progression. SFRP1 was shown to prevent Wnt-induced migration of breast 
cancer cells and to lead to the formation of fewer metastases. The antagonist inhibits 
Wnt signaling in breast cancer cell lines, evidenced by decreased levels of three 
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Dishevelled proteins and lower levels of total and active β-catenin, and results in 
decreased growth and proliferation.  
 
 
Howe and Brown (2004) concluded from their review that overexpression of 
Wnt1 in mouse mammary tissue resulted in hyperplasia rather than carcinoma, 
indicating that Wnt1 could contribute to the establishment of a premalignant state. 
However, Wnt signaling may also contribute to epithelial to mesenchymal transition 
(EMT) and thus promote migration and increase aggressiveness of cancers, and 
subsequently stimulate mesenchymal to epithelial transition (MET) to help the 
establishment of the secondary tumor at the site of metastasis (Neth et al., 2007). 
Supporting the idea of the role of Wnt in tumor invasion, colonic tumor cells located 
at the invasive front of the tumor and migrating cells show elevated nuclear β-catenin 
while cells located within the tumor have membranous β-catenin expression 
comparable to normal cells (Fodde & Brablez, 2007).  
Figure 3: Wnt signaling and breast cancer development.  
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D. Inflammation and Wnt signaling 
A few studies have also investigated the link between obesity-induced 
inflammation and Wnt signaling activity, and although it has not been fully explored 
yet it has led some teams of scientists to wonder whether Wnt could act as an 
intermediate between obesity-induced inflammation and cancer development. Gauger 
et al. (2014) have investigated the effects of high fat diet (HFD) and diet-induced 
obesity (DIO) on Wnt signaling. They showed that Wnt4 was increased by both loss 
of the antagonist SFRP1 and HFD independently, and in the absence of SFRP1 
(Sfrp1-/- mice), HFD and DIO resulted in increased Wnt activation, as evidenced by 
increased expression of the oncogenic Wnt target Myc, and upregulation of active β-
catenin. SFRP5 also seems to play a key role in Wnt activity in obese individuals. 
Ouchi et al. (2010) showed that the Wnt antagonist acts as an anti-inflammatory 
adipokine. SFRP5 is primarily secreted by white adipose tissue, but its expression is 
reduced in obese animals (ob/ob mice and Zucker diabetic fatty rats) as well as in 
mice fed a high fat-high sugar (HF/HS) diet. SFRP5 is known to inhibit Wnt5a and 
Wnt11, and while Wnt11 could not be detected, Wnt5a and Wnt5a to sFRP5 ratio 
were increased in obesity. SFRP5-knocked out mice on the HF/HS diet saw 
significant impairment in glucose tolerance and insulin sensitivity, and showed signs 
of increased inflammatory response (increased macrophage content and increased 
levels of TNF-α, IL-6, and MCP-1). Addition or restauration of sFRP5 reversed those 
effects. Since Wnt antagonists are commonly downregulated in breast cancer (Suzuki 
et al., 2008), these results suggest the potential for Wnt activation in obese women, 
which could contribute to the promotion and progression of breast cancer in those 
individuals. Indeed, DIO and sFRP1 loss resulted in decreased expression of the 
tumor suppressor p53 and the absence of the Wnt inhibitor sFRP1 led to resistance to 
21 
 
anoikis (cell death due to loss of attachment), which is critical for cell survival during 
metastasis (Gauger et al., 2014).  
As mentioned previously, impaired adipogenesis may be one of the 
contributing factors to the link between obesity and inflammation, and Wnt signaling 
is suspected to play an important role in the regulation of adipocytes maturation and 
the mediation of adipose cell cross-communication (Christodoulides et al., 2008). 
Indeed, studies in cell lines and in mice showed that activation of Wnt via increased 
levels of Wnt proteins (Wnt1 and Wnt10b) or inhibition of β-catenin phosphorylation 
prevented preadipocytes differentiation. Conversely, addition of recombinant 
inhibitors (sFRP1 or sFRP2) or increased expression of Axin or dnTCF7L2 (TCF4) 
led to spontaneous differentiation. DKK1, another Wnt antagonist that binds to 
LRP5/6 co-receptors, is expressed during differentiation of human preadipocytes and 
blocks Wnt signaling to promote adipogenesis. 
The cytokines discussed previously might exert their anti-adipogenic functions 
via the activation of Wnt signaling. Indeed, the inhibition of Wnt (via knockdown of 
β-catenin) lessened the inhibitory effects of TNF-α on adipogenesis (Cawthorn et al., 
2007). Gustafson and Smith (2006) showed that IL-6 and TNF-α prevented the 
degradation of β-catenin during adipocytes differentiation thus preventing 
preadipocytes maturation. IL-6 did not alter levels of Wnt proteins but rather allowed 
cytoplasmic and nuclear levels of β-catenin to remain elevated. TNF-α had the same, 
even stronger, effects, and did increase Wnt10b and Pref-1 expression, and also 
increased the expression of CyclinD1, a target gene. Wnt10b is known to prevent 
adipocyte differentiation and is secreted by preadipocytes. Neither the effects of IL-6 
nor of TNF-α were reduced by the presence of the Wnt antagonist sFRP2. The two 
cytokines also maintained high expression of LRP6 and Dsh, and decreased the 
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expression of Axin (which is normally reduced in Wnt signaling). Isakson et al. 
(2009) also found that addition of both Wnt3a and TNF-α individually inhibit 
preadipocyte differentiation, and that Wnt10b was increased in preadipocytes in the 
presence of TNF-α. It thus seems that inflammatory cytokines alter adipocytes 
maturation through the Wnt signaling pathway. Also supporting the idea of a link 
between inflammation and Wnt activation, Ouchi et al. (2010) found that in visceral 
adipose tissue of obese individuals, the presence of CLS is associated with decreased 
levels of the antagonist sFRP5, as well as increased TNF-α. However, they believe 
that sFRP5 acts via the noncanonical Wnt-pathway, based on evidence of increased 
phosphorylation of c-Jun N-terminal kinase (JNK), while the transcription of 
cyclinD1 or WISP2, targets of the canonical pathway, was not influenced by sFRP5. 
The location of tumor cells with β-catenin accumulation within the tumor mass 
suggests that although mutations in APC or β-catenin may initiate Wnt activity, other 
factors, such as growth factors or inflammatory cytokines, may play a key role in 
nuclear β-catenin accumulation (Fodde & Brablez, 2007). As mentioned previously, 
cells located at the invasive front showed elevated nuclear β-catenin while cells within 
the tumor had normal levels. Tumor cells located at the invasive front produce 
extracellular matrix and cytokines and growth factors, which allows them to interact 
with parenchymal cells and thus promotes their proliferative and invasive capacity. 
Some pro-inflammatory cytokines may be able to activate Wnt signaling and thus 
promote cancer development. Macrophage-derived IL-1β has been shown to be a 
strong inducer of Wnt activity in colon tumor cells (Kaler, Augenlicht & Klampfer, 
2009a). IL-1β was sufficient and necessary to activate Wnt signaling, and its 
neutralization prevented macrophages from inducing Wnt activity and clonogenic 
growth of tumor cells, thus reducing macrophages-induced tumorigenesis. Treatment 
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of colon cancer cells with IL-1β resulted in increased phosphorylation of GSK3β and 
increased levels of the target gene c-myc. However, while Kaler et al. (2009b) found 
that IL-1β was a more potent inducer of Wnt activity via TCF4/β-catenin transcription 
than TNF-α, Oguma et al. (2008) and Liu et al. (2012) both found that TNF-α was 
able to initiate Wnt signaling. Oguma et al. (2008) found that in gastric tumors TNF-α 
was able to activate Wnt/β-catenin signaling via increased phosphorylation of GSK3β. 
Exposure of gastric cancer cell lines to activated macrophages resulted in increased 
Wnt activity. Treatment with TNF-α alone produced similar results while blockage of 
either of its two receptors suppressed TNF-α-induced Wnt signaling. Contrary to what 
was found in colon cells by Kaler et al. (2009b), Oguma et al. (2008) found that Wnt 
activity was not promoted by IL-1β, nor by IL-6 or IL-11. They suggest that 
phosphorylation of GSK3β is due to the activation of the Akt pathway by TNF-α. Liu 
et al. (2012) also report that TNF-α, which is elevated in the colon of obese mice, is 
accompanied by increased GSK3β phosphorylation, accumulation of β-catenin, and 
increased expression of the Wnt target c-myc. 
Although not clearly defined yet, a role for Wnt in cell proliferation thus 
seems very likely. It could partially explain the fact that while the relationship 
between obesity and breast cancer risk varies by menopausal status – obesity 
increases breast cancer incidence in post-menopausal women but has no influence or 
may be protective before menopause – high BMI has been linked with increased 
mortality and aggressiveness regardless of menopausal status (Carmichael, 2006). 
This may indicate that obesity-induced inflammation acts primarily on the 
proliferative front rather than at the tumor initiation stage, and that other factors, 
including sex hormones which do vary by menopause status, may regulate tumor 
initiation. Moreover, obesity is a risk factor for the development of triple-negative 
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breast cancer, which is not influenced by sex hormones, in premenopausal women as 
well (Turkoz et al., 2013). Supporting the tumor-promoting role of Wnt, Wnt2 and 
Wnt5a were found to be upregulated in the progression from adenoma to carcinoma in 
colon cancer (Smith et al., 1999). 
 
E. Conclusion 
The link between obesity and breast cancer is well established, but the 
mechanisms involved have not been fully elucidated. Obesity is associated with 
abnormal expansion of WAT, which have been shown to promote the production of 
inflammatory cytokines by M1 macrophages. Obesity-induced inflammation results in 
increased levels of those cytokines in the serum of obese individuals, and preliminary 
evidence show that they may also be present locally in various tissues, including the 
breast. Those cytokines have also been found to be over-expressed in breast tumors 
and are suspected to participate in tumor promotion via the activation of inflammatory 
pathways. However, very few studies have investigated the link between obesity, 
inflammation and cytokines in the breast, and breast cancer. Wnt activity is suspected 
to be elevated in women with breast cancer, evidenced by accumulation of β-catenin. 
Cytokines have been shown to modulate Wnt activity in several cancer cell lines and 
animal models, but the relationship between pro-inflammatory cytokines and Wnt 
activity in human breast tissues has not been investigated. Being able to establish a 
causal relationship between cytokines and Wnt signaling in the breast would greatly 
enhance our understanding of the relationship between obesity and breast cancer, and 
could potentially uncover a new area of investigation for the development of 
treatment options.  
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CHAPTER 3 
PURPOSE OF THE STUDY 
Numerous studies have established that chronic over-nutrition acts as a 
stressor and the resulting obesity-induced inflammation is suspected to play a critical 
role in the development of breast cancer, but the mechanisms involved have not yet 
been fully understood. Inflammatory cytokines, important participants in the immune 
response to inflammation, have been shown to be elevated in the serum as well as 
adipose tissue of obese individuals, and a few studies suggest that they may be present 
in local tissues, including the breasts, as well. However, very little research has been 
conducted on the link between body weight, the presence of inflammatory cytokines 
in breast tissue, and elevated breast cancer risk in humans. Inflammatory cytokines 
are suspected to play a critical role in the activation of several tumorigenic pathways. 
Wnt signaling is believed to be increased in many breast cancer cases (60%), but the 
effects of obesity-induced inflammatory cytokines on the activation of Wnt-signaling 
in mammary tissue is unknown. We therefore propose to characterize the 
inflammatory cytokine profile and determine how Wnt-signaling responds to obesity-
induced inflammation in the breasts of obese postmenopausal women. We also 
propose to investigate whether TNF-α, one of the most critical inflammatory 
cytokines, is a strong inducer of Wnt activity by ex vivo treatment of mammary 
tissues with anti-TNF-α antibody or TNF-α recombinant protein. 
 
Hypothesis 1: The levels of inflammatory cytokines are elevated in the breast 
tissue of obese postmenopausal women 
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Specific Aim 1: Characterize the inflammatory cytokine profile in the mammary 
tissue of lean, overweight, and obese postmenopausal women using a high-
performance, electrochemiluminescence immunoassay (Meso Scale Discovery 
System®). A panel of 6 inflammatory cytokines, IFN-γ, IL-1β, IL-2, IL-6, IL-8, and 
TNF-α, was selected.  
 
Hypothesis 2: Wnt signaling activity is elevated in the breast tissue of obese 
postmenopausal women  
Specific Aim 2: Measure Wnt activity in the mammary tissue of lean, overweight, and 
obese  postmenopausal women using real-time PCR to measure the expression of 7 
Wnt target genes: c-Myc, Cyclin D1, Axin2, COX2, P53, C-Jun, and MAPK8. 
 
Hypothesis 3: Wnt activity in the breasts is regulated by proinflammatory 
cytokines and the blockade or addition of TNF-α will respectively decrease or 
increase Wnt activity 
Specific Aim 3: Measure Wnt activity in the mammary tissue of obese 
postmenopausal women treated with anti-TNF-α antibody and in the tissue of lean 
women treated with recombinant TNF-α protein using real-time PCR to measure the 
expression of 7 Wnt target genes: c-Myc, Cyclin D1, Axin2, COX2, P53, C-Jun, and 
MAPK8. 
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Figure 4: The scheme of the hypothesis.  
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CHAPTER 4 
MATERIALS & METHODS 
Our experiment investigates the relationship between body mass index (BMI) 
and the concentration of inflammatory cytokines in the breast tissue of obese women, 
and their influence on Wnt-signaling activity. The inflammatory cytokines profile in 
the breast tissue of normal weight, overweight and obese women were first evaluated 
using a high-performance electrochemiluminescence immunoassay. The gene 
expression of Wnt target genes was measured in the same women using real-time 
PCR to evaluate the correlation between BMI and Wnt activity. The effects of 
addition or inhibition of the pro-inflammatory cytokine TNF-α on Wnt activity was 
then investigated by measuring the level of expression of Wnt target genes in breast 
tissue samples treated with either anti-TNF-α antibody or TNF-α recombinant protein 
in order to be able to establish a causal relationship between inflammatory cytokines 
and Wnt activation.  
 
A. Breast tissue samples 
Two batches of breast tissues were obtained from Baystate Medical Center in 
Springfield, MA.  
- Batch 1 consists of 31 tumor-free breast samples from women, mostly 
postmeopausal, who underwent elective breast reduction surgery. The average 
BMI is 32.2kg/m², ranging from 21 to 48kg/m². Age and BMI of the 
individuals are summarized in Table 2 in the Appendices.  
- Batch 2 consists of 11 pairs of samples from 5 postmenopausal obese women 
(BMI ranging from 30.4 to 50.1kg/m²) and 6 postmenopausal normal weight 
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or slightly overweight women (23.8 to 26.6kg/m²) who underwent either 
elective surgery or mastectomy to remove a tumor. For each woman, one 
sample remained untreated as the control and one sample underwent 
treatment. Samples from obese women were treated with anti-TNF-α antibody, 
while samples from lean women were treated with TNF-α recombinant 
protein. Age, BMI, tumor condition, and treatment are summarized in Table 3 
in the Appendices. 
Each sample was divided in 3 aliquots. All tissue are preserved at -80°C for the 
duration of the project. 
 
B. Pro-inflammatory cytokines profile 
Tissue samples (one aliquot of Batch 1) were homogenized in a Complete 
Lysis buffer (10-20mg of tissue per 400µL of buffer), and protein concentrations were 
determined using a commercially available BCA kit and a microplate reader 
(SpectraMax M2, by Molecular Devices) following the protocol outline in the 
Appendices. Proteins samples were diluted to the lowest concentration obtained 
(300µg/mL). α 
Concentrations of the pro-inflammatory cytokines IFN-γ, IL-1β, IL-2, IL-6, 
IL-8 and TNF-α were measured using Meso Scale Discovery System®, a high-
performance electrochemiluminescence immunoassay, following the company’s 
protocol which is summarized in the Appendices. 
Pearson correlations were calculated to evaluate the relationships between 
BMI and the protein levels of each cytokine (expressed in ng of cytokine/mg of total 
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protein). The samples were then separated into 2 groups, BMI > 30 and BMI < 30, 
and a t-test was performed to compare the average concentration of each cytokine in 
obese vs. leaner women. P-values of less than 0.05 were used as the cut-off for 
significance. 
 
C. Wnt signaling pathway activity 
RNA was isolated from 1 aliquot of each sample of both Batch 1 and Batch 2 
using TRIzol® Reagent (Ambion® RNA, by Life TechnologiesTM) and following the 
company’s protocol outlined in the Appendices.  
cDNA was synthesized from the RNA samples using QuantiTect® Reverse 
Transcription (Qiagen®) and following the company protocol.  
DNA primers for the target genes of interest (c-Myc, Cyclin D1, Axin2, COX2, 
P53, C-Jun, and MAPK8) were designed using The Massachusetts General Hospital’s 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/) and were ordered from 
InvitrogenTM (InvitrogenTM Custom DNA Oligos, Life Technologies®). A list of the 
primers used can be found in Table 4 in the Appendices. 
The expression of the genes of interest was measured by real-time PCR 
(Applied Biosystems ViiATM 7 RT-PCR System, by Life Technologies®). Gene 
expression was evaluated with ΔCt, using β-actin as the house-keeping gene. ΔCt is 
defined as Ct(target) – Ct (β-actin). The protocol used for real-time PCR can be found in the 
Appendices.  
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a) Wnt activity and BMI 
Gene expression of 7 Wnt targets (c-Myc, Cyclin D1, Axin2, COX2, P53, C-
Jun, and MAPK8) was measured in all 31 samples from Batch 1.   
Pearson correlations were calculated to evaluate the relationships between 
BMI and gene expression (ΔCt values). We also performed a t-test to compare the 
target genes expression in women with BMI > 30 vs. women with BMI < 30. Finally, 
Pearson’s correlations were calculated to investigate the relationship between each 
cytokine and each target gene for which a correlation with BMI was found (IL-6, IL-
1β and TNF-α, and CyclinD1, Axin2 and MAPK8). P-values of less than 0.05 were 
used as the cut-off for significance.  
b) Effects of TNF-α on Wnt activity 
Gene expression of 7 Wnt targets (c-Myc, Cyclin D1, Axin2, COX2, P53, C-
Jun, and MAPK8) will be measured in the 11 controls and corresponding treated 
samples from Batch 2. 
The fold-increase or -decrease in each gene expression was calculated as fold-
change = 2-ΔΔCt, with ΔΔCt = ΔCt(treatment) - ΔCt(control). A paired t-test was performed 
to evaluate the change in gene expression after treatment, and a p-value < 0.05 was 
used as the cut-off for significance.  
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CHAPTER 5 
RESULTS 
A. Pro-inflammatory cytokines profile 
In order to evaluate the inflammatory status of the breasts of normal weight 
(n=5), overweight (n=7) and obese (n=19) women, levels of 6 pro-inflammatory 
cytokines (IFN-γ, IL-1β, IL-2, IL-6, IL-8 and TNF-α) were measured using Meso 
Scale Discovery System®. Pearson’s correlations were calculated to evaluate the 
relationship between BMI and protein concentrations of inflammatory cytokines (in 
ng/mg of total protein) in the breasts of women who underwent breast reduction 
surgery.  
Significant correlations were found between BMI and protein levels of IL-1β, 
IL-6 and TNF-α (p-values were 0.010, <0.001, 0.028 respectively; Figure 5). 
However, the levels of IL-8, IFN-γ, or IL-2 do not seem to be influenced by body 
weight (Figure 6). IL-1β, IL-6 and TNF-α are the cytokines the most often cited in 
relation to obesity and consistently found elevated in the serum of obese individuals, 
so it seems consistent that they would be the ones most elevated in the breast of 
women with high BMIs.  
We then divided the women into two groups: one obese group (BMI>30; 
n=16) and one normal and overweight group (BMI<30; n=9). We combined lean and 
overweight women because of our small sample size. We looked at the difference 
between the average concentrations of each cytokine between the two groups. The 
levels of IL-6 and TNF-α were significantly higher (p-values were 0.011 and 0.014 
respectively) in the obese group compared to the leaner group (Figure 7). The increase 
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in IL-1β was borderline non-significant (p=0.065), and the other cytokines did not 
show any difference between the two groups. 
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Our results thus do suggest that there is a pro-inflammatory environment 
present in the breasts of obese women, evidenced by increasing levels of IL-1β, IL-6 
and TNF-α as BMI increases, which could promote the development of breast tumors. 
Because both obesity and breast cancer have been individually suspected to be linked 
to Wnt signaling, we then investigated the correlation between BMI and Wnt activity 
in human mammary tissue.  
 
B. Wnt-signaling activity and BMI 
The correlation between Wnt activity and BMI was evaluated by measuring 
the levels of gene expression of 7 Wnt targets (Myc, Jun, Cyclin D1, P53, Cox2, 
Axin2, MAPK8) using real-time PCR. Because menopausal status influences breast 
Figure 7: Levels of pro-inflammatory cytokines in obese women (BMI ≥ 30) vs. 
women with BMI less than 30.  
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cancer risk and may impact Wnt activity, only post-menopausal women (>50 years 
old) were included in the analysis (n=25). Pearson’s correlations were calculated to 
evaluate the relationship between gene expression of the 7 target genes (expressed 
using ΔCT) and BMI. 
We found a significant positive correlation between BMI and CyclinD1 
expression (p-value = 0.006; Figure 8a). As BMI increases ΔCT decreases, indicating 
an increase in the gene expression. We also observed a positive trend between BMI 
and Axin2 expression (Figure 8b). Although the correlation is not significant, it seems 
highly influenced by the data point with a BMI of 48kg/m², which acts as an outlier. 
Removal of this data point causes the p-value to drop to 0.028. The expression of the 
other targets was not significantly related to BMI (data not shown).  
A.- 
 
 
 
 
B.-  
 
 
 
 
Figure 8: Correlation between BMI and Wnt targets Cyclin D1 and Axin2 
expression. A.- Cyclin D1 expression increases (ΔCT decreases) with BMI. B.- 
Axin2 expression tends to increase with BMI. 
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We then looked at the difference in gene expression between the two groups 
(BMI > 30 and BMI < 30) using a two sample t-test.  The gene expressions of 
CyclinD1 and Axin2 are significantly higher (p-values are <0.001 and 0.030 
respectively) in the obese group compared to the normal/overweight group (13-fold 
and 3-fold increases respectively; Figure 9). The gene expression of MAPK8 is close 
to also being significantly increased in obese individuals (p=0.058). Although not 
significantly, we note that all the Wnt targets tend to be more expressed in obese 
individuals than in leaner women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As mentioned previously, a few studies have linked Wnt signaling and obesity 
before, and our laboratory has shown that cytokines, and especially TNF-α, may 
regulate Wnt activity (Liu et al., 2012). We therefore think that the elevated levels of 
Figure 9: Expression of Wnt targets in women with BMI ≥ 30 vs. leaner women 
(BMI < 30). 
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cytokines in women with high BMIs described previously may explain the increase in 
Wnt activity. We therefore looked at the correlation between CyclinD1, Axin2 and 
MAPK8 (JNK1) with each cytokine found elevated in the breasts of obese women (IL-
1β, IL-6 and TNF-α) and found that IL-6 was positively correlated with CyclinD1 and 
Axin2 (p-values are 0.028 and 0.048 respectively) and TNF-α was significantly 
correlated with JNK1 expression (p = 0.046; Figure 10). These results may indicate 
that inflammatory cytokines play a role in the increased Wnt activity observed in 
obese women. 
 
C. Effects of TNF-α on Wnt activity 
To evaluate whether there is a causal relationship between elevated cytokines 
and Wnt activity, we compared the expression of the seven Wnt targets in the breast 
tissue of menopausal women after ex-vivo treatment with either anti-TNF-α antibody 
or TNF-α recombinant proteins with non-treated controls.  
We found that the expression of CyclinD1 was significantly decreased by anti-
TNF-α antibody treatment, and increased by addition of TNF-α recombinant protein 
(over 3-fold decrease and increase in comparison to untreated controls; p-values are 
0.031 and 0.023). Anti-TNF-α treatment also decreased the expression of Cox2 4-fold 
(p = 0.017), and TNF-α recombinant protein decreased the expression of tumor 
suppressor p53 2-fold (p = 0.014) and tended to increase Axin2 expression as well (p 
= 0.082). The relative expressions of each gene in each treatment group are 
summarized in Table 1 below.
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Table 1: Relative expression of Wnt targets after treatment with anti-TNF-α 
antibody (women with BMI ≥ 30) and TNF-α recombinant protein (women with 
BMI < 30). 
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CHAPTER 6 
DISCUSSION 
The expansion of adipose tissue observed in obesity is accompanied by an 
increase in the secretion of pro-inflammatory cytokines by the adipocytes, pre-
adipocytes and macrophages that compose WAT, and those cytokines are commonly 
found elevated in the serum of obese individuals. In postmenopausal women 
specifically, Chedraui et al. (2012) showed that levels of IL-6 were elevated in 
women with the metabolic syndrome, a very common condition in obese individuals, 
and correlated with waist circumference. IL-6 and TNF-α also correlated with 
hypertension, another condition often found in obese individuals. Those cytokines 
may travel to other sites and affect distant tissues, including the breasts. Obesity has 
for example been associated with increased levels of TNF-α, IL-1β and IL-18 in the 
colon of obese mice compared to lean animals (Liu et al., 2012). Previous studies 
have shown elevated levels of macrophages, crown-like structures (CLS) and some of 
those inflammatory cytokines, especially IL-6 and TNF-α, in the mammary tissue of 
obese mice (Subbaramaiha et al., 2011; Santander et al.; 2015), but this relationship 
has not been investigated in humans. In this study, we measured the levels of 
proinflammatory cytokines in mammary tissue from postmenopausal women and 
examined their relationships with BMI.   
Out of the six inflammatory cytokines tested, we demonstrated here that the 
levels of three major obesity-related pro-inflammatory cytokines, IL-6, IL-1β and 
TNF-α, are elevated in the breast tissue of obese women, which may create conditions 
favorable to the development of breast cancer. Indeed, cytokines seem to play 
important regulatory roles in tumor progression: some have been found in many cases 
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of breast cancers and are suspected to contribute to cancer development while others 
may have protective effects and are even used in therapeutics (Nicolini, Carpi and 
Rossi, 2006). Tissue levels of IL-1β and IL-6 are associated with tumor cell 
proliferation and invasion, while serum IL-1β and IL-8 are indicators of poor 
prognosis. The effects of IFN-γ seem less clear, and in some cases IFN-γ and IL-2 
have even been used in therapy. Bozcuk et al. (2004) also found that elevated serum 
IL-6 was associated with lower progression free and overall survival in patients 
undergoing chemotherapy. Interestingly, they found that on the contrary elevated 
TNF-α (>6.20pg/mL) was associated with a 52% decreased risk of progression. 
However, other studies have shown that blockade of TNF-α inhibits cell proliferation 
and induces tumor cell apoptosis (Pileczki et al., 2012) and inhibits migration, 
invasion and metastasis (Hamaguchi et al., 2011). These apparently conflicting results 
can be explained by Balkwill’s conclusions that TNF-α, when administered at supra-
physiological levels, has powerful anti-cancer actions, but has tumor promoting 
effects when chronically produced in the tumor microenvironment (Balkwill, 2002). 
In the context of obesity, where TNF-α is chronically elevated, TNF-α should 
therefore be studied for its pro-carcinogenic potential. Indeed, as mentioned 
previously, higher numbers of CLS are found in the breasts of obese women with 
breast cancer than in the breasts of lean women with breast cancer (Morris et al., 
2011), which suggests a higher pro-inflammatory cytokines secretion by 
macrophages. Blot et al. (2003) also showed that monocytes cultivated with breast 
cancer cells show a dramatic increase in TNF-α secretion and significantly reduced 
the pro-apoptotic effects of TNF-α, thus promoting cancer progression. Considering 
that obesity is well-established as a risk factor for breast cancer development 
(especially in post-menopausal women) and is associated with poor prognosis 
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regardless of menopausal status (Carmichael, 2006; Berdaz et al., 2004; Reeves et al., 
2007), and that inflammation is now believed to play a role in this relationship 
(Santander et al., 2015), these findings may justify further research in this area and 
reveal new strategies for breast cancer prevention and treatment. 
Many inflammatory pathways have been investigated for their roles in obesity-
associated diseases. Regarding breast cancer, estrogen is often cited as one of the 
main contributors to the relationship between fat tissue accumulation and breast 
cancer risk. However, it does not seem to explain everything, especially when it 
comes to non-estrogen-responsive tumors. Wnt signaling has recently drawn attention 
since β-catenin accumulation has been found in a large percentage (~60%) of breast 
tumors and has been associated with poor prognosis (Howe & Brown, 2004; Lin et 
al., 2000). Also supporting the importance of Wnt signaling in breast cancer 
development, Mukherjee et al. (2011) showed that Wnt signaling was somehow 
altered in at least one Wnt-related gene in 99% (156/158) of the samples they 
analyzed. As mentioned previously, a few studies have shown that obesity might 
result in increased Wnt activity in the absence of antagonists (Gauger et al., 2014; 
Ouchi et al., 2010), which seem to be often downregulated in breast tumors (Suzuki et 
al., 2008; Mukherjee et al., 2011). Ouchi et al. (2010) also showed that obese 
individuals with CLS express lower levels of Sfrp5, suggesting that obesity might 
promote Wnt activity by down-regulating antagonists. Others have shown that 
cytokines can activate Wnt signaling: Gustafson and Smith (2006) showed that IL-6 
and TNF-α both result in increased Wnt activity (high β-catenin, LRP6 and Dsh and 
low Axin) in preadipocytes, and Kaler, Augenlicht and Klampfer (2009a) showed that 
IL-1β produced by macrophages in colon cancer cells induced Wnt signaling, via the 
NF-κB/AKT pathway (Kaler et al., 2009b).  In this study, after demonstrating that 
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high BMI is associated with an elevated inflammatory status manifested by increased 
levels of IL-1β, IL-6 and TNF-α in postmenopausl mammary tissue, we further 
investigated whether BMI is also associated with aberrant Wnt activity. We found a 
significant correlation between BMI and CyclinD1 expression (p-value = 0.006). 
There was also a 13-fold increase in CyclinD1 expression in obese women in 
comparison to women with BMI < 30. Our findings complete the study by Lin et al. 
(2000) who showed that CyclinD1 expression paralleled β-catenin activity and was a 
predictor of poor patient survival, and the results of Tanić et al. (2013) who showed 
that CyclinD1 was overexpressed in 20% of breast cancer samples and was associated 
with the stage II of breast cancer patient, indicating its involvement in cancer 
progression. CyclinD1 could thus provide a potential explanation for the poor 
prognosis associated with obesity, regardless of menopausal status.  
Axin2 expression was significantly increased (3-fold, p-value = 0.030) in the 
obese group in comparison to the leaner group. There also seems to be a positive 
correlation between BMI and Axin2 expression, although the correlation is not 
significant due to an abnormally high data point (woman with BMI = 48). When this 
point is eliminated the relationship becomes significant (p-value = 0.028) and the 
correlation between BMI and CyclinD1 also becomes even more significant (p-value 
= 0.002). Yook et al. (2006) showed that Axin2 plays a critical role in EMT and 
therefore promotes invasiveness via the zinc-finger transcription factor Snail1. Axin2 
acts both as a tumor suppressor and as an oncogene (Fodde & Brabletz, 2007). It is 
part of the destruction complex and therefore participates in β-catenin degradation, 
and it controls the phosphorylation of Wnt targets (c-Myc, Cyclins, Snail1) by 
GSK3β. However, upon Wnt activation, Axin2 is upregulated and redirects GSK3β to 
the cytoplasm, leaving Snail1 (and other Wnt targets) unphosphorylated and 
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transcriptionally active. Upregulation of Axin2 in women with high BMIs could thus 
promote cancer invasion and aggressiveness, and also contribute to the relationship 
between obesity and poor prognosis for breast cancer patients. We also found that 
JNK1 (MAPK8) was upregulated 7-fold in the obese group (borderline significant: p-
value = 0.058). JNK1 is traditionally considered a target of the non-canonical Wnt 
pathway, but recent studies suggest that the canonical and non-canonical Wnt 
pathways may cooperate and contribute to carcinogenesis (Saadeddin et al., 2009). 
JNK seems to be involved in both cell proliferation and cell apoptosis. Some studies 
report increased tumor formation upon JNK inhibition (Cellurale et al., 2012) while 
others showed that JNK inhibition in breast cancer cells resulted in apoptosis and 
growth inhibition and therefore could be used to decrease proliferation (Mingo-Sion 
et al., 2004). JNK thus seems to participate in normal breast development, but its 
dysregulation may have consequences on tumorigenesis. Interestingly, JNK is 
involved in immunity and is activated by many stressors including the inflammatory 
cytokines TNF-α and IL-1, and inhibits cell growth in inflammatory conditions 
(Mingo-Sion et al., 2004). However, Ouchi et al. (2010) showed that blockade of 
Wnt5a-JNK signaling reduced IL-6 and TNF-α secretion by adipocytes and 
macrophages, and concluded that JNK activation significantly contributes to 
inflammation. Our results are consistent with their finding that Wnt5a and 
Wnt5a:sFRP5 ratio was increased in obesity, and that the presence of CLS was 
associated with decreased sFRP5 antagonist, and resulted in increased activation of 
JNK1. JNK1 has been found to have opposing functions and its role in tumorigenesis 
is not fully understood yet, but because it is influenced by inflammatory mediators 
and that those are abnormally regulated in obesity, further investigation on the 
mechanisms involved would be beneficial. Obesity promotes chronic low-grade 
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inflammation rather than the acute inflammatory response seen in normal immune 
responses and may therefore impair normal JNK regulation.  
One surprising result was that the tumor suppressor p53 was close to being 
significantly up-regulated 8-fold (p = 0.065) in obese women. P53 is regulated by 
many pathways and therefore this increase in its expression may not be due to Wnt 
signaling exclusively. Also, it is important to note that p53 is often altered in breast 
cancer, and that p53 signaling may be significantly impaired in obesity. Indeed, Ford 
et al. (2013) showed that obesity promoted mammary tumor progression in mice 
regardless of the level of expression of p53, and Ayyanan et al. (2005) found that p53 
functions in breast tumors are impaired upon Wnt1 activation. Therefore, elevated 
p53 expression may not be as beneficial as expected upon development of breast 
tumors in obese individuals.  
In addition to the correlation between BMI and Wnt activity, we attempted to 
establish a causal relationship between the presence of inflammatory cytokines and 
Wnt activation. We first looked at the correlation between each elevated inflammatory 
cytokine and each elevated Wnt target, and found that IL-6 correlates with CyclinD1 
and Axin2 expressions, and that TNF-α correlates with JNK1. This may suggest that 
inflammatory cytokines at least partially explain the effects of obesity on Wnt 
activity. TNF-α is one of the main obesity-related inflammatory cytokines, and has 
been shown to activate the Wnt pathway in adipocytes (Gustafson & Smith, 2006; 
Isakson et al., 2009), in the colon of obese mice (Liu et al., 2012), and in gastric 
tumors (Oguma et al., 2008). Oguma et al. also showed that TNF-α inhibition reduced 
Wnt activity while TNF-α protein stimulated it. We thus suspected that TNF-α 
blockade would reduce Wnt activity while addition of TNF-α recombinant protein 
would increase it. We did find that CyclinD1 expression reflected TNF-α treatment: it 
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was increased in samples treated with protein, and reduced in samples treated with 
neutralizing antibody. This is consistent with the study by Cawthron et al. (2007) who 
found, while investigating the effects of TNF-α on adipogenesis, that TNF-α 
treatment resulted in increased CyclinD1 expression, and seems of major interest 
since CyclinD1 is a well-established oncogene in many cancers, including breast 
cancer (Arnold & Papanikolaou, 2005), and has been found elevated in a significant 
portions of human breast tumors (Tanić et al., 2013). Axin2 also seems to be 
upregulated after treatment with TNF-α recombinant protein (p = 0.082), but it was 
not significantly affected by treatment with anti-TNF-α antibody in our study. 
Ayyanan et al. (2005) found Axin2 to be consistently upregulated in human breast 
carcinomas, which further supports our hypothesis that inflammatory cytokines result 
in Wnt activation and thus promote breast tumor development. We also found that 
TNF-α blockade significantly reduced Cox2 expression. Cox2 has been shown to be 
involved in the development of several types of tumors, including breast tumors, and 
is associated with poor prognosis and its expression increases with breast tumor 
progression (Cho et al., 2005). Our data thus suggest that blockade of inflammatory 
cytokines may be an effective way to reduce breast cancer risk, possibly by 
decreasing Wnt activity. Finally, we did find that addition of TNF-α recombinant 
protein reduced p53 expression. As mentioned previously, p53 is often impaired in 
breast cancer (Ford et al., 2013; Ayyanan et al., 2005), and although we found that it 
may be upregulated in obese women who are disease free, these results suggest that 
the elevated levels of TNF-α observed in the breasts of women with high BMI may 
impair its tumor suppressor functions and thus allow breast cancer development. 
Together, these results reveal that TNF-α may be an important mediator between 
obesity and Wnt activation. Although further investigation is required, TNF-α seems 
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to be an important modulator of Wnt signaling and may be considered as a target for 
therapeutics in the treatment of breast cancer.  
Our results thus do indicate the presence of a pro-inflammatory environment 
in the breasts of obese women, and seem to support our hypothesis that inflammation 
causes Wnt activity to increase with BMI. However, a few limitations must be taken 
into consideration when interpreting our results. Our sample size is relatively small 
and we do lack information regarding the donors – we were provided age and BMI 
only – so we may not be accounting for confounders including body fat distribution, 
breast size, parity, actual menopausal status, breast feeding, use of hormone therapy, 
etc. These factors have all been listed as potential risk factors, and therefore further 
studies that control for these would help strengthen our findings. However, while 
many of these are suspected to increase breast cancer risk via the actions of sex 
hormones, we propose a mechanism that is estrogen-independent, and could therefore 
explain the link between obesity and breast cancer risk for both estrogen-responsive 
tumors after menopause and triple negative breast cancer before menopause, and 
between obesity and poor prognosis regardless of menopause status. Most women 
studied for the correlations between BMI and cytokines levels and BMI and Wnt 
activity were disease free, so further research to clearly establish the link between 
Wnt signaling and breast cancer development needs to be done. Previous studies have 
shown increased Wnt activity in breast cancer, and others have shown increased 
presence of macrophages, markers of inflammation, near breast tumors so we suspect 
a link between the two conditions, but further research is necessary and a follow-up to 
investigate whether women with increased BMI and increased Wnt activity develop 
breast tumors more frequently than leaner women would be ideal. On the contrary, 
although all our samples are normal mammary tissues, some of the women from 
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whom samples were obtained for ex-vivo culture with TNF-α recombinant protein or 
anti-TNF-α antibody had breast tumors, which may influence our results. Finally, as 
mentioned above, many, if not all, of the Wnt targets are also influenced by other 
pathways. Our study does not allow us to discriminate between them and therefore 
Wnt signaling may not be the only one at play and the observed aberrant expression 
of the Wnt pathway downstream genes may not exclusively be the consequence of 
obesity-induced inflammation. Nevertheless, our results provide promising evidence 
of a link between obesity-induced inflammation and the activation of Wnt signaling, 
which may influence the development of breast cancer. 
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CHAPTER 7 
SUMMARY & CONCLUSIONS 
Overall, our study provided evidence of a link between obesity-induced 
inflammation and Wnt signaling activation, which may contribute to breast cancer 
development. We were the first laboratory, to our knowledge, to investigate the 
relationship between BMI, inflammatory cytokines and the Wnt pathway in human 
mammary tissue. Although not quite sufficient to determine the exact role of obesity-
driven Wnt signaling in the breast and its implications on breast cancer development, 
our results do show that an inflammatory environment is found in the breasts of obese 
women and is associated with increased Wnt activity, which may drive the 
development of breast cancer. Since Wnt activity is upregulated in the majority of 
breast cancer cases (~60%), these finding are very relevant to the research on the link 
between obesity and cancer. TNF-α, one of the most important inflammatory 
cytokines associated with obesity, may play a role in this relationship. Our results 
demonstrate that its blockade reduces the expression of several Wnt targets, while 
addition of TNF-α recombinant proteins had the opposite effect. We thus outlined a 
potential new mechanism linking obesity-associated inflammation and particularly the 
critical TNF-α, Wnt activity, and possibly breast cancer development and progression, 
which will contribute to our understanding of the relationship between obesity and 
breast cancer. Other inflammatory cytokines are found at high levels in obese 
individuals, including IL-6 and IL-1β, and therefore investigating their roles as well 
would be beneficial and may reveal complementary effects on Wnt signaling. 
Evaluating Wnt activity at different stages of breast cancer development would 
further contribute to our understanding of the role of Wnt in breast cancer. 
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APPENDIX 
SAMPLES AND PROCEDURES
A. Samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
ID 
BMI Age 
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25,8 49 
74 25,9 56 
80 22 52 
81 21 55 
83 25 56 
91 32 56 
92 34 52 
110 32 59 
134 35 56 
140 37 53 
142 26 65 
143 33 66 
147 23 42 
163 28 62 
165 37 65 
166 48 59 
Sample 
ID 
BMI Age 
180 33 51 
190 41 54 
192 41 55 
194 23 43 
211 27,8 57 
213 39,7 46 
214 39 59 
222 42 31 
225 32,6 35 
226 31 61 
233 40 59 
241 28 51 
243 23 56 
249 39 62 
250 32 56 
Sample 
ID 
BMI Age Treatment Surgery 
148 30,4 48 antibody single 
269-R 24,7 53 protein rm 
269-L 24,7 53 protein rm 
286 33,9 50 antibody single 
290-NAB 23,8 50 protein 
 
bilateral 
290-AB 23,8 50 protein bilateral 
307 50,1 67 antibody single 
312-NAB 33,6 52 antibody bilateral 
312-AB 33,6 52 antibody bilateral 
318 25 53 protein single 
336 26,6 59,5 protein single 
Legend:  
rm = reduction mammoplasty 
single = mastectomy of the 
affected side 
bilateral = mastectomy of 
both the affected (AB) and 
non-affected (NAB) sides 
 
Table 2: Sample characteristics (age and BMI) for cytokines profile and Wnt 
activity (Batch 1) 
 
 
 
 
Table 3: Sample characteristics (age, BMI, surgery and treatment) for effects of 
TNF-α on Wnt activity (Batch 2). 
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B. Protein preparation 
Prepare Tris Lysis buffer (1X, Incomplete): 150 mM NaCl; 20 mM Tris, pH 7.5; 1 
mM EDTA; 1 mM EGTA; 1% Trition-X-100 
Store at 2-8°C  
Prepare Complete Lysis Buffer: 10 mL 1X Tris Lysis Buffer; 100μL Phosphatase 
inhibitor I; 100μL Phosphatase inhibitor II; 100μL Protease inhibitor solution 
Preparation of tissue samples  
- Prepare 10~20 mg of tissue per 400 µl Complete Lysis Buffer and put the tissue 
in 2ml microcentrifuge tubes with 400 µl pre-chilled Complete Lysis Buffer.  
- Homogenize (30,000 rpm) using a power homogenizer.  
- Incubate on ice for 30 min.  
- Centrifuge (~12,000 g) for 30 min at 4°C.  
- Remove and discard the fatty layer, transfer the clear supernatant into a new 
tube.  
- Determine the protein concentration using PierceTM BCA protein Assay kit and 
a microplate Reader (SpectraMax M2, by Molecular Devices) 
- Divide into aliquots and store at -80°C.  
 
C. Cytokine profiling (MSD protocol) 
Materials: 
- Proinflammatory Panel 1 (human) Kits (Proinflammatory Panel 1 (human) 
Calibrator Blend; Diluent 2; Diluent 3; Read Buffer T (4X); SULFO-TAG 
Detection Antibodies (IFN-γ, IL-1β, IL-2, IL-6, IL-8, TNF-α). 
- Phophate-buffered saline (PBS) plus 0.05% Tween-20 
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- Deionized water 
Turn on MSD instrument 
Prepare calibrators according to the company’s protocol from the lyophilized 
calibrator 
Prepare samples in 96-well polypropylene plate (so multichannel pipette can be used) 
- For duplicates, place 60µL of sample in well 
- Add 60µL of Diluent 2 (2-fold dilution) 
- Mix well (centrifuge) for a few seconds 
Prepare antibody solution: In one 3-mL tube, add 60µL of each detection antibody, 
and add Diluent 3 to bring total volume to 3000µL (vol. Diluent 3 = 3000 – 60*(# of 
Ab)) 
Prepare the Wash Buffer by combining 15mL of buffer and 285mL of deionized 
water 
Prepare Read Buffer T (2X) by combining 10mL of Read Buffer T (4X) and 10mL of 
deionized water 
Protocol: 
- Add 50µL of sample (or calibrator) per well using a multichannel pipette 
- Seal plate with adhesive tape 
- Incubate at room temperature for 2 hours with shaking (350rpm on plate 
shaker) 
- Wash plate 3 times with 150µL/well of wash buffer 
- Add 25µL of detection antibody solution to each well 
- Seal plate with adhesive tape 
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- Incubate at room temperature for 2 hours with shaking (350rpm on plate 
shaker) 
- Wash plate 3 times with 150µL/well of wash buffer 
- Add 150µL/well of 2X Read Buffer T, using reverse pipetting 
- Read plate using MSD instrument 
 
D. Real-time PCR 
a) Isolate RNA using TRIzol® 
- Homogenize samples (~10mg) in 1mL TRIzol® Reagent in 3-mL centrifuge 
tubes using a power homogenizer.  
- Incubate for 5min at room temperature 
- Add 0.2mL of chloroform, cap the tube and shake vigorously for 15sec. 
- Incubate for 2-3min at room temperature and centrifuge at 12,000 x g for 
15min at 4°C. 
- Remove the aqueous (top) phase and place in new 1.5-mL centrifuge tube 
- Add 0.5mL of 100% isopropanol 
- Incubate at room temperature for 10min, and centrifuge at 12,000 x g for 
10min at 4°C. 
- Remove the supernatant from the tube. 
- Add 1mL of 75% ethanol, vortex briefly, and centrifuge at 7500 x g for 5min 
at 4°C.  
- Discard the wash and air dry the RNA pellet for 5-10min. 
- Resuspend the pellet in 50µL RNase-free water 
- Incubate in a heat block at 55-60°C for 10-15min. 
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- Proceed to cDNA synthesis or store at -70°C. 
b) Perform cDNA synthesis using QuantiTect® Reverse Transcription 
(Qiagen®) 
- Add 2µL of gDNA Wipeout Buffer, 7x; 75ng of RNA; and enough RNase-
free water to bring the volume to 14µL 
- Incubate for 2min at 42°C and place on ice.  
- Add 1µL of Quantiscript Reverse Transcriptase; 4µL of Quantiscript RT 
Buffer, 5x; and 1µL of RT Primer Mix.  
- Incubate for 15min at 42°C, then incubate for 3min at 95°C.  
- Proceed to real-time PCR or store at -20°C. 
c) Perform real-time PCR 
- Prepare the primer mixture: mix 5µL of the forward primer, 5µL of the reverse 
primer, and 90µL of DNase, RNase free distilled water. Primers used are listed 
in Table 4 below. 
- In each well (384- or 96-well plate, or 8-tube strip), add 2µL of DNase/RNase 
free distilled water and 5µL of Power SYBR® Master Mix (Life 
Technologies).  
- Add 1µL of primer mixture 
- Add 2µL of cDNA sample.  
- Cap/seal and centrifuge to eliminate bubbles.  
- Run RT-PCR to measure ΔCT using the standard mode. 
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Wnt 
Targets 
Forward Reverse 
MYCBP 
(Myc) 
ATGGCCCATTACAAAGCCG TTTCTGGAGTAGCAGCTCCTAA 
CCND1 
(CyclinD1) 
GCTGCGAAGTGGAAACCATC CCTCCTTCTGCACACATTTGAA 
AXIN2 CAACACCAGGCGGAACGAA GCCCAATAAGGAGTGTAAGGACT 
TP53 CAGCACATGACGGAGGTTGT TCATCCAAATACTCCACACGC 
PTGS2 
(COX2) 
CTGGCGCTCAGCCATACAG CGCACTTATACTGGTCAAATCCC 
MAPK8 
(JNK) 
TGTGTGGAATCAAGCACCTTC AGGCGTCATCATAAAACTCGTTC 
JUN TCCAAGTGCCGAAAAAGGAAG CGAGTTCTGAGCTTTCAAGGT 
Β-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 
 
  
Table 4: Wnt targets and β-actin (housekeeping gene) primers.  
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